StockData

InnovAge vs P3 Health Partners

INNV and PIII side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How INNV and PIII compare

InnovAge is the larger company, worth 75 times as much as P3 Health Partners ($1.3B against $17.5M).

InnovAge grew revenue faster over the last twelve months (15.9% versus 2.8% for P3 Health Partners).

InnovAge keeps more of each dollar of sales as profit, with a net margin of −0.26% compared with −6.6% at P3 Health Partners.

InnovAge scores higher on the StockData Score (11 against 4 for P3 Health Partners), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricINNVPIII
Size and price
Market cap$1.3B$17.5M
Share price$9.58$2.41
Change, 1 year78.7%−65.6%
Change, 5 years25.9%−99.5%
Beta (5Y)−0.18−0.60
Employees2,500320
StockData Score
Total score11 (better)4
Valuation score01 (better)
Growth score3 (better)1
Performance score3 (better)2
Health score5 (better)0
Dividend score00
Valuation
P/S1.3×0.0× (better)
P/B5.5×–
EV/EBITDA51.2×–
P/FCF25.9×–
FCF yield3.9%–
Fair value$5.76–
Margin of safety−66.3%–
Growth
Revenue growth (TTM)15.9% (better)2.8%
Revenue growth, 5Y average9.2%24.3% (better)
Profitability
Gross margin23.0%–
Operating margin0.26% (better)−9.9%
Net margin−0.26% (better)−6.6%
FCF margin5.1%–
Return on equity−1.1% (better)−221%
Return on invested capital1.2% (better)−62.4%
Financial health
Debt / equity0.20–
Net debt / EBITDA−3.93–
Current ratio1.05 (better)0.46
Altman Z-score4.27 (better)−0.19
Piotroski F-score6 (better)2
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions13.5%65.0%
Held by insiders75.4%98.0%
Insider net buying, 12 months−$227M−$824K (better)
Short interest, % of float2.7%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.